FDA Approves Dabigatran For Reduction of Risk and Recurrence of deep venous thrombosis and pulmonary embolism

Fetal_thrombotic_vasculopathy

The U.S. Food and Drug Administration (FDA) has approved the anticoagulant dabigatran (Pradaxa) “for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated,” according to a press release External Link from Boehringer Ingelheim Pharmaceuticals, Inc. Continue reading

Advertisements